Medtronic’s sham-controlled renal denervation study, SYMPLICITY HTN-3, has failed to meet its primary efficacy endpoint of significantly reducing office blood pressure between baseline and six months in patients with treatment-resistant hypertension and systolic blood pressure of ≥160mmHg. (Source Vascularnews, Friday 10th, 2014)

Covidien announced this past week that it is exiting the Renal Denervation program and is going to halt its RAPID II program.

What this means for us as patients is that we should not proceed with renal denervation as a treatment for our hypertension.